LYON, France, March 12 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and distribution of a wide portfolio of minimally invasive medical devices primarily for the treatment of urological diseases announces it signed a letter of intent with LMA Urology Suisse S.A. to exclusively distribute the StoneBreaker system in LMA's French territory.

The LMA Stonebreaker^™ is a portable intra-corporeal contact lithotripter, intended to fragment stones in the urinary tract. This handheld system complements lithotripsy procedures performed with ESWL devices by targeting stones located in places which cannot be reached with an extra- corporeal shockwave generator. The system, manufactured in Switzerland, received the CE mark in June 2006 and validated by extensive clinical trials confirming the effectiveness of this cynetic intracorporeal lithotripsy technique.

Pierre Reboul, Sales Director France commented: "The addition of this new system to our portfolio is in line with the Company's strategy to expand on our strong knowledge of the French medical community and our long lasting dedicated network. Our leadership and recognized presence on the French lithotripsy market will help us leverage our expertise in addressing the French Urology market."

Marc Oczachowski, Chief Operating Officer of EDAP TMS added, "The addition of the StoneBreaker system to our range of lithotripsy devices clearly complements our ESWL portfolio, thus widening our scope on the lithotripsy market. It allows us to offer the best option to French Urologists looking for the most adapted therapeutic solution for their patients with urinary stones. Over the last 25 years, EDAP TMS proved its ability to bring new therapeutic devices to market and today benefits from a strong ESWL installed base and a supportive medical network, which makes us confident of a successful launch for the LMA StoneBreaker^™ in France."

Mr. Paul Molloy, President of LMA Urology Suisse S.A., said, "LMA^™ is very excited to be working with EDAP in France where it is widely recognized as a pioneering and innovative market leader. We are confident that the addition of our LMA StoneBreaker^™ device to the EDAP portfolio is going to benefit both companies and bring a new standard of care to those suffering from stone disease."

About LMA

LMA designs, develops, markets and distributes medical equipment, principally the LMA laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA- Classic, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market. For more information about LMA, please see http://www.lmaurology.com .

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Magnolia Investor Relations at (972) 801-4900, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com .

To sign up for alerts please visit http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm- HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

     CONTACT:  EDAP TMS S.A.            Magnolia Investor Relations
               Blandine Confort         Matt Kreps
               +33 4 78 26 40 46        972 801 4900

CONTACT: Blandine Confort of EDAP TMS S.A., +33-4-78-26-40-46; or Matt
Kreps of Magnolia Investor Relations, +1-972-801-4900, for EDAP TMS S.A.

Web site: http://www.edap-tms.com/
http://www.hifu-planet.com/
http://www.lmaurology.com/
http://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0/